Moderna (NASDAQ:MRNA) Stock Price Up 4.9% - Here's Why

Moderna logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Moderna shares rose 4.9% to about $209.11 on Friday, though trading volume was 89% below its average.
  • Investors are watching the company’s personalized melanoma vaccine: in a Phase 3 trial with Merck’s Keytruda, it reduced recurrence or death risk by 42%. The result bolsters the oncology pipeline, but the timing of potential revenue remains uncertain.
  • Analysts’ consensus rating is Hold, with an average price target of $120.25. Moderna also reported quarterly EPS of $0.38 and revenue of $1.31 billion, both above consensus estimates.
  • MarketBeat previews the top five stocks to own by December 1st.

Shares of Moderna, Inc. (NASDAQ:MRNA - Get Free Report) shot up 4.9% during trading on Friday. The company traded as high as $209.48 and last traded at $209.1080. 1,417,480 shares traded hands during mid-day trading, a decline of 89% from the average session volume of 12,430,554 shares. The stock had previously closed at $199.33.

More Moderna News

Investors following MRNA have been watching these news items:

  • Positive Sentiment: Moderna’s personalized melanoma vaccine, used with Merck’s Keytruda, reduced the risk of recurrence or death by 42% in a Phase 3 trial. The result supports the potential of Moderna’s oncology pipeline, although it does not yet resolve questions about how quickly the program could generate revenue. Article
  • Negative Sentiment: Investors are weighing a reported $4 billion in projected 2027 cash costs against uncertain revenue growth. A report says MRNA fell 17% in a week, reflecting concern over whether its vaccine business can finance oncology investments and other growth plans. Article
  • Negative Sentiment: Shares reportedly fell below their 50-day moving average amid the selling, adding a technical concern after the stock’s substantial rally. Article

Analyst Ratings Changes

A number of research analysts have issued reports on MRNA shares. Weiss Ratings reissued a "sell (d-)" rating on shares of Moderna in a research note on Wednesday, September 9th. Rothschild & Co Redburn downgraded shares of Moderna from a "neutral" rating to a "sell" rating and lifted their price objective for the company from $40.00 to $81.00 in a research report on Thursday, September 3rd. Berenberg Bank raised their price objective on shares of Moderna from $45.00 to $100.00 and gave the stock a "hold" rating in a research report on Friday, September 11th. Wolfe Research raised Moderna from an "underperform" rating to a "peer perform" rating in a report on Tuesday, August 25th. Finally, Morgan Stanley boosted their price objective on shares of Moderna from $95.00 to $200.00 and gave the company an "equal weight" rating in a research report on Tuesday. Six research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $120.25.

Check Out Our Latest Analysis on MRNA

Moderna Price Performance

The company's 50 day moving average price is $206.87 and its 200-day moving average price is $99.61. The stock has a market cap of $79.63 billion, a P/E ratio of -27.75 and a beta of 1.16. The company has a quick ratio of 3.47, a current ratio of 3.62 and a debt-to-equity ratio of 0.52.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings data on Friday, November 6th. The company reported $0.38 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.10) by $1.48. The company had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $890.25 million. Moderna had a negative return on equity of 25.79% and a negative net margin of 110.46%. The firm's revenue was up 29.2% compared to the same quarter last year. During the same period last year, the company earned ($0.51) earnings per share. As a group, sell-side analysts expect that Moderna, Inc. will post -5.40 earnings per share for the current year.

Insider Buying and Selling at Moderna

In related news, insider Shannon Klinger sold 3,471 shares of the business's stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total transaction of $485,766.45. Following the transaction, the insider owned 74,129 shares in the company, valued at $10,374,353.55. The trade was a 4.47% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO James M. Mock sold 34,836 shares of the firm's stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the completion of the sale, the chief financial officer owned 59,375 shares of the company's stock, valued at $7,985,343.75. The trade was a 36.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 275,626 shares of company stock valued at $50,776,076. 10.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in MRNA. Cim Investment Management Inc. bought a new stake in Moderna in the 3rd quarter worth about $290,000. PCM Encore LLC increased its stake in shares of Moderna by 24.6% in the third quarter. PCM Encore LLC now owns 3,944 shares of the company's stock worth $760,000 after purchasing an additional 779 shares in the last quarter. First National Bank of Hutchinson bought a new position in Moderna in the 3rd quarter worth approximately $597,000. Defiance ETFs LLC purchased a new stake in shares of Moderna during the third quarter worth $517,000. Finally, Harbor Advisors LLC purchased a new position in shares of Moderna in the third quarter valued at $385,000. 75.33% of the stock is currently owned by institutional investors and hedge funds.

About Moderna

(Get Free Report)

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company's commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Moderna Right Now?

Before you consider Moderna, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.

While Moderna currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Related Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines